Monoclonal antibodies (mAbs) are useful therapeutics for targeted treatments in oncology, autoimmune disorders, and infectious diseases. Among the key distinctions in therapeutic mAbs are those labeled fully human and humanized. Both rely heavily on animal models (primarily mice) and genetic engineering techniques to achieve their therapeutic properties.

Biointron’s AbDrop platform revolutionizes antibody discovery by combining high-throughput screening with advanced microfluidic technology, enabling the identification of diverse and high-affinity antibodies. This process starts by isolating plasma B cells from immunized animals, encapsulating them in microdroplets to preserve natural heavy and light chain pairing, a critical factor for developing functional therapeutic antibodies.

Biointron’s AbDrop & Cyagen’s HUGO-Ab is a high-throughput fully human antibody discovery platform that combines microdroplet-based single B cell screening with transgenic mice. This combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months.

The development of chimeric antibodies was a significant turning point in antibody engineering. To engineer more human-like antibodies, researchers combined the variable regions of antibodies from one species with the constant regions of another, resulting in increased antigen specificity with reduced immunogenicity. This was a key advance in making antibodies more suitable for therapeutic applications in humans.

The 22nd Annual Discovery on Target 2024 was held in Boston, MA on September 30 to October 3, 2024. This four-day event involved discussion on popular topics like kinases, immunomodulation, and degraders, plus coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models.

In the immune system, antibodies are responsible for identifying and neutralizing foreign invaders such as pathogens. They achieve this through the precise recognition of antigens, a process largely determined by the structure of their variable regions. Each antibody is composed of two types of protein chains: the heavy chain (HC) and the light chain (LC). These two chains form a highly specific pairing that is necessary for the antibody's ability to bind to its target antigen.

Explore how single-cell antibody sequencing reveals immune diversity by analyzing individual B cells, offering precise insights into antibody repertoire & therapeutic discovery.

Explore groundbreaking high-throughput screening techniques, including phage display and microfluidics, advancing single B cell screening for therapeutic antibody discovery.

Learn how clear IP in biotech fosters innovation & collaboration while eliminating royalty fees for antibody discovery. Discover its impact on drug development today!

Discover why transgenic mice are essential for producing fully human antibodies. Learn how humanized immune systems improve antibody specificity & affinity in vivo.

Discover how microfluidic technology in biotechnology is revolutionizing drug discovery, diagnostics & antibody screening. Learn more about its impact on precision medicine!

Explore how fully human antibodies reduce immunogenicity, enhance therapeutic efficacy, and enable personalized treatments, supported by advanced transgenic technologies.

Discover the efficiency of AbDrop™ & HUGO-Ab™ for rapid, fully human antibody discovery using microfluidics & TurboKnockout® technology in just 3 months.

Explore advances in Single B Cell Screening, including microfluidics, deep sequencing & multiplexing, revolutionizing antibody discovery for infectious diseases. Learn more!

Antibody Engineering & Therapeutics Europe 2024 was held in London, UK on 4-6 June, 2024. As Europe's leading antibody conference for accelerating next-generation antibodies to commercial success, topics discussed included:Emerging modalities: ADCs, degraders, and beyondFc